Angiosarcoma is a rare and aggressive cancer that requires a combination of treatments tailored to each patient’s situation. The goals of therapy include removing the tumor, controlling symptoms, slowing disease progression, and improving quality of life. Because this cancer can appear in many parts of the body and behaves differently from person to person, doctors use both established treatments and explore new options through clinical research.

How Treatment Is Planned for This Rare Cancer

When someone is diagnosed with angiosarcoma, the treatment plan depends on several important factors. The location of the tumor makes a big difference—whether it appears on the skin, in an organ like the liver or heart, or in deeper tissues. The size of the tumor and whether it has spread to other parts of the body also shape the treatment approach. Doctors also consider the patient’s overall health and ability to tolerate different therapies.^[1]

Because angiosarcoma is so rare—affecting only about one person per million each year—medical teams typically work together in a multidisciplinary approach. This means surgeons, oncologists who specialize in chemotherapy, radiation specialists, and other experts collaborate to create the best plan for each patient. Standard treatments that have been approved by medical societies exist, but researchers are also constantly testing new therapies in clinical trials to find better ways to fight this disease.^[3]

The stage of the disease plays a crucial role in deciding treatment. Stage 1 and 2 angiosarcomas are considered localized and may be easier to treat with surgery. Stage 3 and 4 tumors have spread more extensively and often require a combination of treatments. Even with aggressive treatment, angiosarcoma tends to come back, which is why long-term monitoring and sometimes additional therapy are necessary.^[4]

Standard Treatment Options

Surgery: The Main Treatment When Possible

Surgery is the primary treatment for angiosarcoma whenever the tumor can be completely removed. The goal is to take out not just the cancer but also a border of healthy tissue around it. This border, called a margin, helps ensure that no cancer cells are left behind. Surgeons aim for what is called “negative margins,” meaning the edges of the removed tissue show no cancer cells under the microscope.^[7]

The type of surgery depends on where the angiosarcoma is located. For tumors on the skin of the head, neck, or scalp, surgeons remove the visible tumor plus surrounding tissue. When angiosarcoma affects the breast—especially in women who previously received radiation therapy for breast cancer—the usual treatment is removal of the entire breast, known as a mastectomy. This is because these radiation-related tumors tend to be widespread within the breast tissue.^[7]

If angiosarcoma develops in an arm or leg, surgeons typically perform limb-sparing surgery, which removes the tumor while keeping the limb functional. However, in rare cases where the cancer has spread throughout the limb, a partial or full amputation may be necessary to stop the disease. For angiosarcoma in organs like the heart, specialized cardiovascular surgeons perform complex operations to remove as much tumor as possible, though this can be extremely challenging due to the tumor’s invasive nature.^[7][9]

Radiation Therapy: Killing Cancer Cells With High-Energy Beams

Radiation therapy uses powerful energy beams, such as X-rays or protons, to destroy cancer cells. This treatment is often used after surgery to kill any microscopic cancer cells that might remain in the area. By targeting these leftover cells, radiation helps reduce the chance that the tumor will grow back in the same location.^[11]

For patients who cannot have surgery—perhaps because the tumor is too large, in a location that makes surgery impossible, or has spread to multiple areas—radiation therapy may be used as the main treatment. Sometimes doctors combine radiation with chemotherapy to make the treatment more effective. This combination approach is especially considered when the tumor cannot be safely removed without causing severe harm to vital structures.^[11]

In cutaneous angiosarcoma, particularly on the scalp, combining radiation therapy with weekly paclitaxel (a type of chemotherapy drug) has shown promising results. This combination can produce durable responses, meaning patients may remain cancer-free for extended periods. The radiation is delivered in carefully planned doses over several weeks to maximize cancer cell destruction while limiting damage to healthy tissue.^[12]

Chemotherapy: Drugs to Stop Cancer Growth

Chemotherapy involves using powerful drugs or chemicals that kill cancer cells or stop them from dividing and growing. These medications travel through the bloodstream, reaching cancer cells throughout the body. This makes chemotherapy particularly important when angiosarcoma has spread to distant organs like the lungs or liver—a situation called metastatic disease.^[8]

Several chemotherapy drugs are used to treat angiosarcoma. Paclitaxel is considered especially effective for this cancer and is usually given weekly through an intravenous infusion. Many patients tolerate this drug relatively well, and it has shown good activity even in people whose cancer has progressed despite previous treatments. Doxorubicin is another important drug, often used as part of anthracycline-based regimens. This medication works by damaging the DNA inside cancer cells, preventing them from multiplying.^[10][12]

Doctors also use combination chemotherapy regimens, which pair two or more drugs together. Examples include gemcitabine combined with docetaxel, gemcitabine with vinorelbine, or doxorubicin with dacarbazine. These combinations may be more effective than single drugs, though they also tend to cause more side effects. The choice of regimen depends on many factors, including the patient’s overall health, previous treatments, and how aggressive the cancer is.^[12]

Common side effects of chemotherapy include fatigue, nausea, hair loss, increased risk of infections due to low white blood cell counts, and numbness or tingling in the hands and feet (called peripheral neuropathy). Some drugs like doxorubicin can affect the heart, so doctors monitor heart function during treatment. Not everyone experiences all side effects, and many can be managed with supportive medications and care.^[10]

The duration of chemotherapy varies. Some patients receive it for a set number of cycles—often between three and six cycles given every few weeks—while others continue treatment as long as it is working and the side effects are tolerable. After completing chemotherapy, patients are monitored regularly with imaging scans to check for any signs that the cancer is returning.^[10]

Treatment in Clinical Trials

Targeted Therapy: Aiming at Cancer’s Weak Points

Because angiosarcoma develops from blood vessel cells, researchers have focused on drugs that target the biological pathways involved in blood vessel growth. One key pathway involves vascular endothelial growth factor, or VEGF, a protein that helps tumors grow new blood vessels to supply themselves with nutrients. Drugs that block VEGF or its receptors (called VEGF inhibitors) are being studied in clinical trials.^[11][13]

Pazopanib is a targeted drug that blocks several different receptors involved in blood vessel growth and tumor cell division. In clinical studies, some patients with angiosarcoma who had already received standard chemotherapy showed responses to pazopanib, with tumors shrinking or remaining stable for a period of time. In one study of patients with advanced vascular sarcomas including angiosarcoma, eight out of 40 patients responded to pazopanib, with a median time before the disease worsened of about three months. While these results are modest, they offer hope for patients whose cancer has not responded to other treatments.^[12]

Another drug being explored is sorafenib, which also targets blood vessel growth pathways. Early research has shown variable results, with some patients benefiting while others do not. Scientists have discovered that patients whose tumors have specific genetic changes—amplifications in genes related to blood vessel receptors—may be more likely to respond to these targeted drugs. This finding suggests that genetic testing of tumors could help identify which patients might benefit most from targeted therapy.^[12]

Researchers are also investigating whether common medications might help fight angiosarcoma. Propranolol, a drug normally used to treat high blood pressure and heart conditions, blocks certain receptors called beta-receptors. Some small studies have combined propranolol with low-dose chemotherapy drugs like vinblastine and methotrexate. In one study of seven patients with advanced angiosarcoma, all showed responses, with one patient’s cancer disappearing completely and three others showing significant tumor shrinkage. Patients lived a median of 16 months. Based on these promising early results, propranolol received orphan drug status in Europe for soft tissue sarcoma treatment in 2017.^[12]

Immunotherapy: Enlisting the Body’s Defenses

Immunotherapy is a type of treatment that helps the patient’s own immune system recognize and attack cancer cells more effectively. The immune system normally protects the body from infections and abnormal cells, but cancer cells often develop ways to hide from immune surveillance. Immunotherapy drugs can remove these disguises or boost the immune system’s cancer-fighting abilities.^[3]

Several types of immunotherapy are being studied in angiosarcoma. Some work by blocking proteins called checkpoint inhibitors that cancer cells use to evade the immune system. When these checkpoints are blocked, immune cells called T-cells can better recognize and destroy cancer cells. While immunotherapy has shown remarkable success in some cancer types, research in angiosarcoma is still in relatively early stages, and scientists are working to understand which patients might benefit most from these approaches.^[3]

Understanding Clinical Trial Phases

When new treatments are developed, they go through a careful testing process in clinical trials. Phase I trials are the first studies in humans and focus mainly on safety. Researchers want to find out what dose can be given safely, what side effects occur, and how the body processes the drug. These trials typically involve small numbers of patients, often those whose cancer has not responded to standard treatments.^[3]

Phase II trials test whether the new treatment actually works against the cancer. These studies involve more patients and carefully measure whether tumors shrink, stop growing, or whether patients live longer. Researchers also continue to monitor for side effects. If a Phase II trial shows promising results, the treatment moves forward to larger studies.^[3]

Phase III trials are the largest and most definitive studies. They compare the new treatment directly against the current standard treatment to see which works better. These trials often involve hundreds of patients at multiple hospitals or cancer centers, sometimes in different countries. If a Phase III trial shows that the new treatment is more effective or has fewer side effects than the standard treatment, it may be approved by regulatory agencies for general use.^[3]

Who Can Participate in Clinical Trials

Patients with angiosarcoma may be eligible to participate in clinical trials depending on various factors. These include the stage and location of the cancer, what treatments have already been tried, and the patient’s overall health. Some trials specifically seek patients whose cancer has spread or returned after initial treatment, while others test treatments in newly diagnosed patients.^[3]

Clinical trials are conducted at major cancer centers and academic medical institutions around the world, including locations in the United States, Europe, and other regions. Patients interested in clinical trials should discuss this option with their oncology team, who can help determine which trials might be appropriate and assist with the referral process. Participating in a trial gives patients access to cutting-edge treatments while also contributing to research that may help future angiosarcoma patients.^[3]

Most common treatment methods

• Surgery
  • Wide surgical resection with removal of tumor and surrounding healthy tissue margin
  • Limb-sparing surgery for tumors in arms or legs to preserve function
  • Mastectomy for breast angiosarcoma, especially radiation-induced cases
  • Cardiovascular surgery for cardiac angiosarcoma performed by specialized surgeons
  • Goal is achieving negative margins to prevent recurrence
• Radiation therapy
  • High-energy beams (X-rays or protons) to destroy cancer cells
  • Used after surgery to eliminate remaining microscopic cancer cells
  • Primary treatment option when surgery is not feasible
  • Combined with weekly paclitaxel for cutaneous angiosarcoma showing promising results
  • May be combined with chemotherapy for enhanced effectiveness
• Chemotherapy
  • Paclitaxel administered weekly, highly effective for angiosarcoma
  • Doxorubicin and other anthracycline-based regimens
  • Gemcitabine-based combinations with docetaxel, vinorelbine, or dacarbazine
  • Used for metastatic disease or when surgery cannot be performed
  • Sometimes given before surgery to shrink large tumors
• Targeted therapy
  • Pazopanib targeting VEGF receptors and tumor growth pathways
  • Sorafenib for blocking blood vessel formation
  • Propranolol combined with low-dose chemotherapy showing promise in small studies
  • Tested in clinical trials for patients with advanced or recurrent disease
  • May work better in patients with specific genetic changes in tumors
• Immunotherapy
  • Checkpoint inhibitor drugs to help immune system recognize cancer cells
  • Being studied in clinical trials for angiosarcoma
  • May be combined with other treatments for enhanced effect
  • Research ongoing to identify which patients benefit most